A Retrospective Analysis of Medical Management Strategies for Trigeminal Neuralgia: An Institutional Review

Background Neuropathic pain results from nervous system damage, and trigeminal neuralgia (TN), also called tic douloureux, is a chronic disorder affecting the trigeminal nerve. TN causes sudden, severe, recurring facial pain that can be highly disabling. Treatment usually involves medications like carbamazepine, oxcarbazepine, gabapentin, or baclofen to manage nerve pain. If medications are ineffective, surgical interventions like microvascular decompression or gamma knife radiosurgery may be explored for symptom relief. Aim and objectives This study aims to assess the demographic characteristics and clinical features of patients with TN treated at a private institution. The objective was to assess key demographic factors, including age, gender, and the affected trigeminal nerve divisions, with a focus on identifying the most frequently involved nerve divisions in TN cases. Methodology This five-year retrospective study (January 2019-April 2023) in the Oral Medicine and Radiology Department analyzed 483 TN cases, including 300 patients with confirmed primary TN and complete records. Dental Information Archive System (DIAS) data covered demographics, clinical features, treatments, and outcomes. Pain levels were assessed using the visual analog scale (VAS). LFTs monitor the long-term effects of medications like carbamazepine. Statistical analysis employed descriptive statistics, chi-square tests, and t-tests, with p < 0.05 considered significant. Results Of 7,500 outpatients in the Oral Medicine Department, 483 were diagnosed with TN, and 300 met the diagnostic criteria for inclusion in a five-year study (January 2019-April 2023). The average age was 60 years for men and 58.5 years for women. TN primarily affected the right side in 158 patients (56%), while the left side was involved in 114 (43%) of the cases (p = 0.04) and most commonly involved the maxillary nerve (V2) in 159 patients (53%) and the mandibular nerve (V3) in 141 patients (47%), with a slight female predominance (p = 0.02). One hundred thirty-five patients (45%) used carbamazepine alone, while 84 were treated with carbamazepine and gabapentin, and 81 were treated with carbamazepine and baclofen. The combination of carbamazepine and gabapentin was the most effective, achieving pain control in 123 patients (75%) compared to 94 patients (70%) with carbamazepine alone and 119 patients (72%) with carbamazepine and baclofen (p = 0.06). VAS scores showed better pain relief with carbamazepine and gabapentin (VAS: 3.8 ± 1.0), carbamazepine alone (mean VAS: 4.5 ± 1.2) and carbamazepine with baclofen (mean VAS: 4.2 ± 1.1). In long-term management, 45 patients (15%) discontinued due to side effects, while 105 patients (35%) continued on carbamazepine alone, 90 patients (30%) on carbamazepine with gabapentin, and 60 patients (20%) on carbamazepine with baclofen (p = 0.04). LFTs were performed on 240 patients (80%), while 60 patients (20%) did not undergo LFTs. Conclusions This study underscores the treatment of TN, with anticonvulsants as the primary therapy and alternative options available for refractory cases. However, limitations like small sample size and lack of long-term follow-up affect the findings' generalizability. The results highlight the importance of treatment plans and the potential advantages of combination therapies in clinical practice.